Want to see JP:2784 full AI Analyst Report?
Top Page
Alfresa Holdings
(2784)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥2,634.00
▲(13.27% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily supported by a strong, low-debt balance sheet and steady revenue growth, while being held back by inconsistent cash-flow conversion and thin operating margins. Valuation is a positive offset (low P/E and ~3% yield), but technical indicators remain weak-to-neutral with the price below key long-term moving averages.
Positive Factors
Conservative Balance Sheet
Very low leverage gives Alfresa financial flexibility to support operations, absorb industry volatility, and fund investment without relying heavily on external financing. A growing equity base also strengthens resilience and reduces solvency pressure across the business cycle.
Negative Factors
Structurally Thin Margins
Thin margins leave limited room for execution errors, cost increases, or adverse pricing movements before earnings are affected. Because modest changes in operating costs can materially influence profit, sustained earnings growth may remain difficult despite revenue expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage gives Alfresa financial flexibility to support operations, absorb industry volatility, and fund investment without relying heavily on external financing. A growing equity base also strengthens resilience and reduces solvency pressure across the business cycle.
Read all positive factors
Alfresa Holdings (2784) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥460.85B
Dividend Yield2.86%
Average Volume (3M)390.99K
Price to Earnings (P/E)11.2
Beta (1Y)0.47
Revenue Growth4.61%
EPS Growth43.22%
CountryJP
Employees12,525
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)216.01
Shares Outstanding191,300,000
10 Day Avg. Volume414,210
30 Day Avg. Volume390,986
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.91
Price to Sales (P/S)0.15
P/FCF Ratio28.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)132.36
Revenue Forecast (FY)¥3.20T
Alfresa Holdings Business Overview & Revenue Model
Company Description
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic re...
How the Company Makes Money
Alfresa Holdings makes money primarily by acting as an intermediary in the pharmaceutical supply chain, purchasing pharmaceuticals and other healthcare products from manufacturers and selling them to customers such as hospitals, clinics, and pharm...
Alfresa Holdings Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.13T | 3.10T | 2.96T | 2.86T | 2.70T | 2.59T |
| Gross Profit | 218.81B | 217.88B | 202.71B | 196.36B | 182.26B | 178.31B |
| EBITDA | 75.92B | 77.41B | 54.56B | 57.44B | 51.96B | 61.08B |
| Net Income | 39.22B | 41.75B | 27.39B | 29.56B | 25.79B | 32.18B |
Balance Sheet | ||||||
| Total Assets | 1.51T | 1.51T | 1.44T | 1.45T | 1.34T | 1.30T |
| Cash, Cash Equivalents and Short-Term Investments | 192.07B | 193.07B | 177.09B | 213.76B | 160.12B | 180.44B |
| Total Debt | 30.00B | 35.62B | 35.55B | 34.94B | 3.85B | 5.04B |
| Total Liabilities | 1.02T | 999.11B | 957.63B | 967.76B | 851.51B | 832.15B |
| Stockholders Equity | 485.64B | 507.36B | 481.79B | 479.60B | 488.09B | 471.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 16.11B | -10.87B | 73.64B | -9.63B | 21.54B |
| Operating Cash Flow | 0.00 | 38.57B | 5.64B | 86.38B | 13.09B | 36.55B |
| Investing Cash Flow | 0.00 | -8.72B | -24.92B | -14.22B | -20.54B | 2.30B |
| Financing Cash Flow | 0.00 | -14.05B | -23.53B | -19.70B | -12.92B | -29.15B |
Alfresa Holdings Technical Analysis
Positive
2325.50
Price Trends
2296.50
Positive
2249.31
Positive
2325.15
Positive
Market Momentum
41.46
Negative
63.74
Neutral
75.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2784, the sentiment is Positive. The current price of 2325.5 is above the 20-day moving average (MA) of 2314.72, above the 50-day MA of 2296.50, and above the 200-day MA of 2325.15, indicating a bullish trend. The MACD of 41.46 indicates Negative momentum. The RSI at 63.74 is Neutral, neither overbought nor oversold. The STOCH value of 75.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2784.
Alfresa Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥372.68B | 10.65 | 9.19% | 3.81% | 4.65% | 23.21% | |
72 Outperform | ¥607.92B | 14.75 | 7.26% | 2.33% | 4.17% | 15.59% | |
69 Neutral | ¥414.84B | 13.20 | 11.15% | 3.72% | 4.32% | 0.18% | |
63 Neutral | ¥460.85B | 11.17 | 7.93% | 2.86% | 4.61% | 43.22% | |
62 Neutral | ¥501.33B | 15.86 | 9.94% | 1.36% | 8.97% | -29.54% | |
56 Neutral | ¥403.59B | 21.09 | ― | 0.35% | 12.54% | 15.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:2784
Alfresa Holdings
2,440.00
358.06
17.20%
JP:7459
Medipal Holdings
3,374.00
923.72
37.70%
JP:9989
Sundrug Co
3,562.00
-484.78
-11.98%
JP:7649
Sugi Holdings Co
1,286.00
-353.98
-21.58%
JP:9987
Suzuken Co
2,895.50
55.21
1.94%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,205.00
425.51
11.26%
Alfresa Holdings Corporate Events
Alfresa’s Q1 Profits Slide Despite Higher Sales, Full-Year Outlook Intact
Aug 5, 2026
Alfresa Holdings reported consolidated net sales of ¥788.96 billion for the quarter ended June 30, 2026, up 4.1% year on year, but profits fell sharply as operating profit dropped 19.6% to ¥5.6 billion and profit attributable to owners o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.